본문 바로가기
KERD
논문KCI 등재

치료저항성 조현병: 정의와 임상양상

Treatment-Resistant Schizophrenia: Terminology and Clinical Features

이건석
대한조현병학회 (Korean Academy of Schizophrenia)|2020.10|대한조현병학회지 (Korean Journal of Schizophrenia Research)|제23권 제2호|pp. 45-50|DOI 10.16946/kjsr.2020.23.2.45

1

조회

0

다운로드

3

인용

0

참고문헌

키워드

임상양상·조현병·치료순응도·치료저항성·클로자핀.Clinical feature · Clozapine · Compliance · Schizophrenia · Treatment-resistance
주제분류정신과학

초록

Schizophrenia is one of serious mental illnesses and is often described as a heterogeneous disorder. Approximately one-third of schizophrenia cases are treatment-resistant schizophrenia (TRS). The aim of this study was to review the definitions and clinical features of TRS. Though it was found that the criteria for TRS were considerably diverse, the Treatment Response and Resistance in Psychosis (TRRIP) consensus criteria were recently introduced. According to the TRRIP criteria, TRS should be suspected if symptoms persist alongside psychotic symptoms despite sufficient treatment for ≥12 weeks, or two or more symptoms persist significantly for ≥6 weeks. The clinical characteristics of TRS includes an earlier age of onset, more severe and familial form, possibly more rural residence, unlikely association with male sex, and an increase in cognitive deficits.

Abstract

Schizophrenia is one of serious mental illnesses and is often described as a heterogeneous disorder. Approximately one-third of schizophrenia cases are treatment-resistant schizophrenia (TRS). The aim of this study was to review the definitions and clinical features of TRS. Though it was found that the criteria for TRS were considerably diverse, the Treatment Response and Resistance in Psychosis (TRRIP) consensus criteria were recently introduced. According to the TRRIP criteria, TRS should be suspected if symptoms persist alongside psychotic symptoms despite sufficient treatment for ≥12 weeks, or two or more symptoms persist significantly for ≥6 weeks. The clinical characteristics of TRS includes an earlier age of onset, more severe and familial form, possibly more rural residence, unlikely association with male sex, and an increase in cognitive deficits.

참고문헌 (43)

  1. Saha S, "A systematic review of the prevalence of schizophrenia", PLoS Med, 2, pp.e141~ (2005)
  2. Kane J, "Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine", Arch Gen Psychiatry, 45, pp.789~796 (1988)
  3. Farde L, "Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects", Arch Gen Psychiatry, 49, pp.538~544 (1992)
  4. Kane JM, "Psychopharmacologic treatment of schizophrenia", Schizophr Bull, 19, pp.287~302 (1993)
  5. Kinon BJ, "Treatment of neuroleptic-resistant schizophrenic relapse", Psychopharmacol Bull, 29, pp.309~314 (1993)
  6. Barnes TR, "Pharmacological treatment strategies in the non-responsive schizophrenic patient", Int Clin Psychopharmacol, 11(Suppl 2), pp.67~71 (1996)
  7. Lehman AF, "Practice guideline for the treatment of partients with schizophrenia, second edition", Am J Psychiatry, 161, pp.1~56 (2004)
  8. Hasan A, "World Federation of Societies of Biological Psychiatry (WFSBP)guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance", World J Biol Psychiatry, 13, pp.318~378 (2012)
  9. National Institute for Health and Care Excellence, "Psychosis and schizophrenia in adults: prevention and management" (2014), National Institute for Health and Care Excellence
  10. Jung Suk Lee, "Korean Medication Algorithm for Schizophrenia 2019, Second Revision: Treatment of Psychotic Symptoms", Clinical Psychopharmacology and Neuroscience, 18(3), pp.386~394 (2020), 대한정신약물학회[DOI]
  11. Howes OD, "Treatment-resistant schizophrenia : Treatment Response and Resistance in Psychosis(TRRIP)working group consensus guidelines on diagnosis and terminology", Am J Psychiatry, 174, pp.216~229 (2017)
  12. Elkis H, "Treatment-resistant schizophrenia", Psychiatr Clin North Am, 30, pp.511~533 (2007)
  13. Essock SM, "Clozapine’s effectiveness for patients in state hospitals : results from a randomized trial", Psychopharmacol Bull, 32, pp.683~697 (1996)
  14. Lieberman JA, "Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia", J Clin Psychiatry, 60(Suppl 12), pp.9~12 (1999)
  15. Lindenmayer JP, "Treatment refractory schizophrenia", Psychiatr Q, 71, pp.373~384 (2000)
  16. Thorup A, "Young males have a higher risk of developing schizophrenia : a Danish register study", Psychol Med, 37, pp.479~484 (2007)
  17. Meltzer HY, "Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance", Am J Psychiatry, 154, pp.475~482 (1997)
  18. Teo C, "The role of ethnicity in treatment refractory schizophrenia", Compr Psychiatry, 54, pp.167~172 (2013)
  19. Wimberley T, "Predictors of treatment resistance in patients with schizophrenia : a population-based cohort study", Lancet Psychiatry, 3, pp.358~366 (2016)
  20. Povlsen UJ, "Tolerability and therapeutic effect of clozapine : a retrospective investigation of 216 patients treated with clozapine for up to 12 years", Acta Psychiatr Scand, 71, pp.176~185 (1985)
  21. Kuha S, "Long-term effect of clozapine in schizophrenia a retrospective study of 108 chronic schizophrenics treated with clozapine for up to 7 years", Nord Psykiatr Tidsskr, 40, pp.225~230 (1986)
  22. Meltzer HY, "Clinical studies on the mechanism of action of clozapine:the dopamine-serotonin hypothesis of schizophrenia", Psychopharmacology (Berl), 99(Suppl), pp.S18~S27 (1989)
  23. Vassos E, "Meta-analysis of the association of urbanicity with schizophrenia", Schizophr Bull, 38, pp.1118~1123 (2012)
  24. Ripke S, "Genome-wide association analysis identifies 13 new risk loci for schizophrenia", Nat Genet, 45, pp.1150~1159 (2013)
  25. Joober R, "Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients", Schizophr Res, 77, pp.35~41 (2005)
  26. Kinon BJ, "The Group of Treatment Resistant Schizophrenias. Heterogeneity in treatment resistant schizophrenia (TRS)", Front Psychiatry, 9, pp.757~ (2018)
  27. Iasevoli F, "Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones", Prog Neuropsychopharmacol Biol Psychiatry, 65, pp.34~48 (2016)
  28. Kennedy JL, "The social and economic burden of treatment-resistant schizophrenia : a systematic literature review", Int Clin Psychopharmacol, 29, pp.63~76 (2014)
  29. Rebecca Schennach, "Treatment Response in First-episode Schizophrenia", Clinical Psychopharmacology and Neuroscience, 10(2), pp.78~87 (2012), 대한정신약물학회[DOI]
  30. Hollis C, "Adult outcomes of child-and adolescent-onset schizophrenia : diagnostic stability and predictive validity", Am J Psychiatry, 157, pp.1652~1659 (2000)
  31. Reichert A, "The psychopathological and psychosocial outcome of early-onset schizophrenia : preliminary data of a 13-year follow-up", Child Adolesc Psychiatry Ment Health, 2, pp.6~ (2008)
  32. Kayo M, "Does lack of improvement in the first two weeks predict treatment resistance in recent-onset psychosis?", Clinics, 67, pp.1479~1482 (2012)
  33. Joober R, "Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers", Schizophr Res, 53, pp.229~238 (2002)
  34. de Bartolomeis A, "Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses", Psychiatry Res, 210, pp.387~395 (2013)
  35. Frydecka D, "Profiling cognitive impairment in treatment-resistant schizophrenia patients", Psychiatry Res, 235, pp.133~138 (2016)
  36. Hippius H, "A historical perspective of clozapine", J Clin Psychiatry, 60(Suppl 12), pp.22~23 (1999)
  37. Crilly J, "The history of clozapine and its emergence in the US market : a review and analysis", Hist Psychiatry, 18, pp.39~60 (2007)
  38. Chakos M, "Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia : a review and meta-analysis of randomized trials", Am J Psychiatry, 158, pp.518~526 (2001)
  39. Üçok A, "Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia", Int Clin Psychopharmacol, 30, pp.290~295 (2015)
  40. Mouaffak F, "Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia", Clin Neuropharmacol, 29, pp.28~33 (2006)
  41. Samanaite R, "Biological predictors of clozapine response : a systematic review", Front Psychiatry, 9, pp.327~ (2018)
  42. Okhuijsen-Pfeifer C, "Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders : a systematic review and meta-analysis", Neurosci Biobehav Rev, 111, pp.246~252 (2020)
  43. Maccall C, "Clozapine : more than 900 mg", day may be needed, 2009, pp.23, 206~210

관련 논문AI추천

치료 저항성 조현병의 이해와 치료김의태대한신경정신의학회 · 신경정신의학2018 · 제57권 제3호치료 위저항성 조현병: 치료 비순응을 중심으로김혜림, 이승재대한조현병학회 · 대한조현병학회지2020 · 제23권 제2호클로자핀의 지연된 사용이 치료저항성 조현병 환자의 급성기 약물 반응에 미치는 영향박선영, 박재섭, 양소영, 최정규대한조현병학회 · 대한조현병학회지2021 · 제24권 제2호조현병 스펙트럼 장애의 1년 유지 치료에서 클로자핀과 병용 치료제의 처방 양상 분석강태욱, 권준수, 김민아, 김세현, 김재원, 문선영, 장진혁대한생물정신의학회 · 생물정신의학2021 · 제28권 제2호10년 이상 치료를 받은 조현병 환자의 재발 요인갈민재, 김원형, 김지현, 김철응, 배재남, 이정섭, 조진우대한조현병학회 · 대한조현병학회지2015 · 제18권 제2호치료저항성 환청을 지닌 정신분열병 환자의 임상특성 및 신경인지기능서광윤, 송형석, 이승환, 정영조, 최병훈대한신경정신의학회 · 신경정신의학2004 · 제43권 제3호

이 간행물의 다른 논문 (4건)

치료 위저항성 조현병: 치료 비순응을 중심으로김혜림, 이승재pp. 51-57조현병 관련 주요 일간지 기사에 대한 텍스트 마이닝 분석남희정, 유승형pp. 58-64유럽인 자료로 산출된 조현병 다유전자 위험도 점수의 한국인 조현병 환자를 대상으로 한 적용홍경수, 백지현, 조은영, 이동빈, 이진영pp. 65-70조현병 환자에서의 지연성 운동이상 발생과 세로토닌 1A 수용체유전자 rs6295 다형성과의 연관성이윤정, 조아름, 이헌정, 남궁윤pp. 71-77
원문 보기